Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry of Multiple Osteonchodromas (REM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04133285
Recruitment Status : Enrolling by invitation
First Posted : October 21, 2019
Last Update Posted : February 10, 2021
Sponsor:
Information provided by (Responsible Party):
Luca Sangiorgi, Istituto Ortopedico Rizzoli

Brief Summary:

REM is a retrospective and prospective registry, finalized to care and research. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc..

This approach has been individuated in order to corroborate and integrate data from different resources and aspects of the diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate diseases pathophysiology.


Condition or disease
Multiple Osteochondroma

Detailed Description:

The common way to collect patient information is frequently chaotic and inconvenient (sometimes even unsafe), particularly when dealing with rare diseases. The need to simplify the diagnostic process and to overcome the difficulties of data storage and analysis, suggested in 2013 to implement the Registry of Multiple Osteochondromas (REM).

The REM relies on an IT Platform named Genotype-phenotype Data Integration platform -GeDI.This solution, realized by a collaboration among Medical Genetic Department and a local software-house (NSI - Nier IT Solution), is a General Data Protection Regulation (GDPR)-compliant, multi-client, web-accessible system and it has been designed according to current medical informatics standards (Orphanet code, ICD-10, Human Genome Variants Society, Findability Accessibility Interoperability Reusability Principles). GeDI is continuously implemented to improve management of persons with Multiple Osteochodromas and to help researchers in analysing collected information. REM is articulated in main sections:

  • Personal data: it comprises general information, birth details and residence data
  • Patient data: including the patients internal code, the hospital code and other details on patients
  • Diagnosis: the diagnosis, the status (affected, suspect, etc.), age at diagnosis, comorbidities, allergies, etc.
  • Genogram: a tool to design family transmission of the disease, flanked by info on diseases status of all included relatives
  • Clinical events: records more than 20 signs and symptoms of Multiple Osteochondromas and 12 additional items to describe the disease
  • Genetic Analysis and Alteration: including technique, sample information, duration of analysis, etc. In addition, this section comprises detailed information on detected pathological variants (gene, international reference, DNA change, Protein change, genomic position, etc.)
  • Visits: it includes the typology of the visit (genetic, orthopaedic, rehabilitation, paediatric, etc.), the date of the visit, treatment, prescription, imaging, etc.
  • Surgeries: this section contains information on the surgeries type, the age of the patients, the site/localization of the procedures, etc.
  • Documents: this repository is allowed to store all type of documents (radiological reports, imaging, consents, clinical reports, etc.)
  • Consents: this section comprises a complete overview of all collected consents, including the date of collection.
  • Samples: it comprises the type of samples (DNA, tissue, whole peripheral blood, etc.)

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration: 15 Years
Official Title: Registry of Multiple Osteochondromas That Collects Clinical, Functional, Genetic, Genealogical, Imaging, Surgical, Quality of Life Data. Data Are Linked to Patients Biological Sample
Actual Study Start Date : June 28, 2013
Actual Primary Completion Date : July 2018
Estimated Study Completion Date : December 2032


Group/Cohort
Multiple Osteochondromas patients
Patients affected by Multiple Osteochondromas. The Registry will include also data on foetuses (prenatal).



Primary Outcome Measures :
  1. Natural History and Epidemiology in terms of clinical, genetic and functional evaluation [ Time Frame: 25 years ]

    To maintain an established registry in order to assess epidemiology and natural history (such as incidence, prevalence, etc.) of Multiple Osteochondromas.

    Collection of:

    1. physical examinations data: assessment of severity of the disease (defined according to Mordenti et al classification)
    2. orthopaedic and functional data: stature (cm), weight (kg), number and localization of sites affected by osteochondromas, site of malignant transformation, definition of deformities (localization and number), definition of limitations (localization and number)
    3. surgical procedures: type, number and site of surgeries disease-related and age at surgeries
    4. genetics background: target gene, type of mutation, type of variant detected, clinical significance
    5. family history: inheritance in maternal or paternal line

    Clinical, orthopaedic and functional features are updated at each follow up. Clinical reports, medical charts, genetic report and imaging are the primary source of data.



Secondary Outcome Measures :
  1. Genotype-Phenotype Correlation among clinical features and molecular background [ Time Frame: 25 years ]
    The secondary outcome comprises the correlation between genotype and phenotype. This includes, but is not limited to clinical features and genetic background. This will be pursued using the information collected during visits and follow-ups and the genetic information resulting from molecular investigations.


Other Outcome Measures:
  1. Longitudinal study of disease evolution (including prospective and retrospective data) [ Time Frame: 25 years ]

    This outcome aims to investigate the evolution of Multiple Osteochondromas during time. This will be evaluated within the families and among the families.

    Main clinical features, such as height (cm), number and localization of osteochondromas, number and localization of deformities, number and localization of limitations will be collected both retrospectively and prospectively for paediatric population. An evaluation of these parameters will be performed at each visit to keep trace on the progression of the clinical manifestations.

    In adult population, the disease evolution is centered on malignant transformation.



Biospecimen Retention:   Samples With DNA
Whole peripheral blood, DNA, lymphocytes, cartilage tissues, bone tissues


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients affected by Multiple Osteochondromas. The Registry will include also data on foetuses (prenatal).
Criteria

Inclusion Criteria:

  • All Multiple Osteochondromas patients, including prenatal diagnosis of Multiple Osteochondromas

Exclusion Criteria:

  • Any condition unrelated to Multiple Osteochondromas

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04133285


Locations
Layout table for location information
Italy
Irccs Istituto Ortopedico Rizzoli
Bologna, Emilia Romagna, Italy, 40136
Sponsors and Collaborators
Luca Sangiorgi
Investigators
Layout table for investigator information
Principal Investigator: Luca Sangiorgi, MD, PhD, MS Istituto Ortopedico Rizzoli
Publications:

Layout table for additonal information
Responsible Party: Luca Sangiorgi, Haed of Medical Genetic Department and Clinical Bioinformatic Laboratory, Istituto Ortopedico Rizzoli
ClinicalTrials.gov Identifier: NCT04133285    
Other Study ID Numbers: 21629/2013
First Posted: October 21, 2019    Key Record Dates
Last Update Posted: February 10, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Luca Sangiorgi, Istituto Ortopedico Rizzoli:
Disease Registry
Natural History Study
Genotype-Phenotype Correlation
Multiple Exostoses
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteochondroma
Exostoses, Multiple Hereditary
Osteochondromatosis
Exostoses
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Osteochondrodysplasias
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Hyperostosis
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn